ITeos Therapeutics Inc [ITOS] stock prices are down -2.01% to $7.81 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ITOS shares have gain 17.18% over the last week, with a monthly amount glided 25.56%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
ITeos Therapeutics Inc [NASDAQ: ITOS] stock has seen the most recent analyst activity on May 14, 2025, when Leerink Partners downgraded its rating to a Market Perform but kept the price target unchanged to $9 for it. Previously, H.C. Wainwright downgraded its rating to Neutral on May 14, 2025. On May 13, 2025, downgrade downgraded it’s rating to Neutral. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $31 on August 13, 2024. H.C. Wainwright initiated its recommendation with a Buy and recommended $37 as its price target on May 05, 2021. Robert W. Baird started tracking with a Outperform rating for this stock on October 08, 2020, and assigned it a price target of $45. In a note dated August 18, 2020, Wedbush initiated an Outperform rating and provided a target price of $45 on this stock.
The stock price of ITeos Therapeutics Inc [ITOS] has been fluctuating between $4.80 and $18.70 over the past year. Currently, Wall Street analysts expect the stock to reach $11.33 within the next 12 months. ITeos Therapeutics Inc [NASDAQ: ITOS] shares were valued at $7.81 at the most recent close of the market. An investor can expect a potential return of 45.07% based on the average ITOS price forecast.
Analyzing the ITOS fundamentals
Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at -4.35%, Pretax Profit Margin comes in at -3.41%, and Net Profit Margin reading is -3.74%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.21 and Total Capital is -0.25. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.68 points at the first support level, and at 7.55 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.99, and for the 2nd resistance point, it is at 8.17.
Ratios To Look Out For
It’s worth pointing out that ITeos Therapeutics Inc [NASDAQ:ITOS]’s Current Ratio is 14.13. Also, the Quick Ratio is 14.13, while the Cash Ratio stands at 4.12. Considering the valuation of this stock, the price to sales ratio is 8.54, the price to book ratio is 0.53.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, 10% Owner, that happened on May 15 ’25 when 3.3 million shares were purchased. 10% Owner, EcoR1 Capital, LLC completed a deal on May 14 ’25 to buy 1.66 million shares. Meanwhile, Former 10% Owner GADICKE ANSBERT sold 1.03 million shares on May 13 ’25.
